The Journal of Thoracic and Cardiovascular Surgery
Volume 128, Issue 4 , Pages 602-608 , October 2004

Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest

  • Tanveer A. Khan, MD

      Affiliations

    • Department of Surgery, Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass, USA
    • ,
  • Cesario Bianchi, MD, PhD

      Affiliations

    • Department of Surgery, Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass, USA
    • ,
  • Pierre Voisine, MD

      Affiliations

    • Department of Surgery, Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass, USA
    • ,
  • Jun Feng, MD, PhD

      Affiliations

    • Department of Surgery, Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass, USA
    • ,
  • Jeralyn Baker, CCP

      Affiliations

    • Department of Surgery, Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass, USA
    • ,
  • Melanie Hart, PhD

      Affiliations

    • Department of Anesthesiology, Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass, USA
    • ,
  • Minoru Takahashi, PhD

      Affiliations

    • Department of Anesthesiology, Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass, USA
    • ,
  • Greg Stahl, PhD

      Affiliations

    • Department of Anesthesiology, Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass, USA
    • ,
  • Frank W. Sellke, MD

      Affiliations

    • Department of Surgery, Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass, USA
    • Corresponding Author InformationAddress for reprints: Frank W. Sellke, MD, Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, 110 Francis St, LMOB 2A, Boston, MA 02215, USA

Received 21 October 2003 ,Revised 9 February 2004 ,Accepted 17 March 2004.

References 

  1. Kloner RA, Jennings RB. Consequences of brief ischemia (stunning, preconditioning, and their clinical implications—part 1). Circulation. 2001;104:2981–2989
  2. Kloner RA, Jennings RB. Consequences of brief ischemia (stunning, preconditioning, and their clinical implications—part 2). Circulation. 2001;104:3158–3167
  3. Sellke FW, Boyle EM, Verrier ED. Endothelial cell injury in cardiovascular surgery (the pathophysiology of vasomotor dysfunction). Ann Thorac Surg. 1996;62:1222–1228
  4. Park JL, Lucchesi BR. Mechanisms of myocardial reperfusion injury. Ann Thorac Surg. 1999;68:1905–1912
  5. Ambrosio G, Tritto I. Reperfusion injury (experimental evidence and clinical implications). Am Heart J. 1999;138:S69–75
  6. Mojcik CF, Levy JH. Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann Thorac Surg. 2001;71:745–754
  7. Bull DA, Maurer J. Aprotinin and preservation of myocardial function after ischemia-reperfusion injury. Ann Thorac Surg. 2003;75:S735–739
  8. McCarthy RJ, Tuman KJ, O'Connor C, Ivankovich AD. Aprotinin pretreatment diminishes postischemic myocardial contractile dysfunction in dogs. Anesth Analg. 1999;89:1096–1100
  9. Hendrikx M, Rega F, Jamaer L, Valkenborgh T, Gutermann H, Mees U. Na(+)/H(+)-exchange inhibition and aprotinin administration (promising tools for myocardial protection during minimally invasive CABG). Eur J Cardiothorac Surg. 2001;19:633–639
  10. Pruefer D, Buerke U, Khalil M, Dahm M, Darius H, Oelert H, et al.  Cardioprotective effects of the serine protease inhibitor aprotinin after regional ischemia and reperfusion on the beating heart. J Thorac Cardiovasc Surg. 2002;124:942–949
  11. Sunamori M, Sultan I, Suzuki A. Effect of aprotinin to improve myocardial viability in myocardial preservation followed by reperfusion. Ann Thorac Surg. 1991;52:971–978
  12. Gurevitch J, Barak J, Hochhauser E, Paz Y, Yakirevich V. Aprotinin improves myocardial recovery after ischemia and reperfusion. Effects of the drug on isolated rat hearts. J Thorac Cardiovasc Surg. 1994;108:109–118
  13. Sunamori M, Innami R, Amano J, Suzuki A, Harrison CE. Role of protease inhibition in myocardial preservation in prolonged hypothermic cardioplegia followed by reperfusion. Effect of aprotinin in an experimental model. J Thorac Cardiovasc Surg. 1988;96:314–320
  14. Khan TA, Ruel M, Bianchi C, Voisine P, Komjati K, Szabo C, et al.  Poly(ADP-ribose) polymerase inhibition improves postischemic myocardial function after cardioplegia-cardiopulmonary bypass. J Am Coll Surg. 2003;197:270–277
  15. Uematsu M, Gaudette GR, Laurikka JO, Levitsky S, McCully JD. Adenosine-enhanced ischemic preconditioning decreases infarct in the regional ischemic sheep heart. Ann Thorac Surg. 1998;66:382–387
  16. Bianchi C, Wakiyama H, Faro R, Khan T, McCully JD, Levitsky S, et al.  A novel peroxynitrite decomposer catalyst (FP-15) reduces myocardial infarct size in an in vivo peroxynitrite decomposer and acute ischemia-reperfusion in pigs. Ann Thorac Surg. 2002;74:1201–1207
  17. Amsterdam EA, Stahl GL, Pan HL, Rendig SV, Fletcher MP, Longhurst JC. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol. 1995;268:H448–457
  18. Diaz PE, Fishbein MC, Davis MA, Askenazi J, Maroko PR. Effect of the kallikrein inhibitor aprotinin on myocardial ischemic injury after coronary occlusion in the dog. Am J Cardiol. 1977;40:541–549
  19. Bukhari EA, Krukenkamp IB, Burns PG, Gaudette GR, Schulman JJ, al-Fagih MR, et al.  Does aprotinin increase the myocardial damage in the setting of ischemia and preconditioning?. Ann Thorac Surg. 1995;60:307–310
  20. Wendel HP, Heller W, Michel J, Mayer G, Ochsenfahrt C, Graeter U, et al.  Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage. J Thorac Cardiovasc Surg. 1995;109:1164–1172
  21. Hendrikx M, Jiang H, Gutermann H, Toelsie J, Renard D, Briers A, et al.  Release of cardiac troponin I in antegrade crystalloid versus cold blood cardioplegia. J Thorac Cardiovasc Surg. 1999;118:452–459
  22. Asimakopoulos G, Thompson R, Nourshargh S, Lidington EA, Mason JC, Ratnatunga CP, et al.  An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation. J Thorac Cardiovasc Surg. 2000;120:361–369
  23. Hayashi Y, Sawa Y, Ohtake S, Fukuyama N, Nakazawa H, Matsuda H. Peroxynitrite formation from human myocardium after ischemia-reperfusion during open heart operation. Ann Thorac Surg. 2001;72:571–576
  24. Hallett MB, Shandall A, Young HL. Mechanism of protection against “reperfusion injury” by aprotinin. Roles of polymorphonuclear leucocytes and oxygen radicals. Biochem Pharmacol. 1985;34:1757–1761
  25. Aoki M, Jonas RA, Nomura F, Stromski ME, Tsuji MK, Hickey PR, et al.  Effects of aprotinin on acute recovery of cerebral metabolism in piglets after hypothermic circulatory arrest. Ann Thorac Surg. 1994;58:146–153
  26. Kadletz M, Dignan RJ, Loesser KE, Hess ML, Wechsler AS. Ischemia and activated neutrophils alter coronary microvascular but not epicardial coronary artery reactivity. J Thorac Cardiovasc Surg. 1994;108:648–657
  27. Vinten-Johansen J, Edgerton TA, Hansen KJ, Carroll P, Mills SA, Cordell AR. Surgical revascularization of acute (1 hour) coronary occlusion (blood versus crystalloid cardioplegia). Ann Thorac Surg. 1986;42:247–254
  28. Bolling K, Kronon M, Allen BS, Wang T, Ramon S, Feinberg H. Myocardial protection in normal and hypoxically stressed neonatal hearts (the superiority of blood versus crystalloid cardioplegia). J Thorac Cardiovasc Surg. 1997;113:994–1003 discussion 1003-5
  29. Ibrahim MF, Venn GE, Young CP, Chambers DJ. A clinical comparative study between crystalloid and blood-based St Thomas' hospital cardioplegic solution. Eur J Cardiothorac Surg. 1999;15:75–83
  30. Flack JE, Cook JR, May SJ, Lemeshow S, Engelman RM, Rousou JA, et al.  Does cardioplegia type affect outcome and survival in patients with advanced left ventricular dysfunction? Results from the CABG Patch Trial. Circulation. 2000;102:III84, 89

☆ Funding was provided by National Institutes of Health grants R01 HL46716 (F.W.S.) and NRSA 1F32 HL69651 (T.A.K.) and by the Bayer Corporation.

PII: S0022-5223(04)00433-7

doi: 10.1016/j.jtcvs.2004.02.037

The Journal of Thoracic and Cardiovascular Surgery
Volume 128, Issue 4 , Pages 602-608 , October 2004

Article Tools

* Image Usage & Resolution